 Home > Medical News > Latest Medical News > Public hospital market, these pharmaceutical companies have the largest sales (with list)

Public hospital market, these pharmaceutical companies have the largest sales (with list)

 Last Update: 2022-11-04
 Source: Internet
 Author: User

Tags

biological processes examples

1 20 ratio

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In 2022, China's pharmaceutical industry will face transformation and upgrading
.

Affected by uncertainties such as the in-depth promotion of centralized procurement and the multi-point spread of the new crown epidemic, in the first half of 2022, the drug sales of China's public medical institutions were 638.
2 billion yuan, an increase of 1.
1% compared with the first half of 2021.

2018-2022H1 Overall sales and growth of terminal drugs in public medical institutions in China

01.
Biological drugs soared 11.
4% The growth rate of proprietary Chinese medicine surpassed that of chemical drugs for the first time in ten years

From the perspective of the distribution of drugs, in the first half of 2022, chemical drugs accounted for the largest proportion in public medical institutions, exceeding 66%, but their market position continued to decline, and sales decreased by 0.
8% year-on-year; The proportion of proprietary Chinese medicines was 19.
3%, a year-on-year increase of 1.
2%, and its market position was relatively stable in the past three years; The proportion of biopharmaceuticals is relatively small, but the market share of biopharmaceuticals continues to rise, the market position continues to improve, and the growth rate of sales in the first half of 2022 reached 11.
4%, which is much higher than the growth rate
of chemical drugs and proprietary Chinese medicines.

2022H1 Proportion of sales of terminal drugs by drug type in public medical institutions in China

02.
Township health centers are the only terminals with a year-on-year decline in sales growth rate of -6.
4%

Among the first terminal public hospitals, urban public hospitals are the main channels for patients to seek medical treatment, and the medication categories in the first half of 2022 are mainly
therapeutic drugs for severe and serious diseases such as tumors, cardiovascular and cerebrovascular, and diabetes, as well as for emergencies.
The demand for rigid drugs makes the drug sales of urban public hospitals account for the largest proportion of drugs used in public medical institutions, nearly 65%.

At the same time, affected by factors such as the spread of the epidemic in many places and the implementation period of more batches of collective procurement varieties, the growth rate of urban public medical institutions is relatively slow, with a year-on-year increase of 1.
7%.

County-level public hospitals accounted for 22.
6% of the drugs used in public medical institutions, a year-on-year increase of 1.
2%.

Community health service center (station) is a chronic disease management center, chronic disease drugs dominate in this channel, with the further promotion of the hierarchical diagnosis and treatment system, as well as the sinking of drug sales channels of enterprises, long prescriptions and other factors jointly promote the growth of the market of community health service centers (stations) drugs, in the first half of 2022, the sales of drugs in community health service centers (stations) increased by 3.
7% year-on-year, which is the fastest growing market
.

After the outbreak of the new crown epidemic, people paid more attention to health and hygiene, which reduced the number of common and frequent diseases, resulting in a decrease
in the demand for medication.
At the same time, the fifth batch of centralized procurement implemented at the end of 2021 also has a relatively large impact on the drug sales of township health centers, so the sales growth rate of township health centers in the first half of 2022 is negative at -6.
4%, which is the only market
in the four markets of medical terminals to decline.

2022H1 Distribution map of drug sales in the four major markets of China's public medical institutions

03.
The decline of generic drugs is smaller than that of original drugs Centralized procurement promotes the market substitution of some generic drugs to original drugs

Generic drugs dominate the terminal market of China's public medical institutions, accounting for 69% in the first half of 2022, with a year-on-year growth rate of -0.
6%, and its decline is lower than that of original drugs
.

Under the normalization of centralized procurement, the substitution trend of selected varieties of generic drugs for the original drug varieties is obvious
.

The sales of original drugs in China's public medical institutions accounted for about 30%, a year-on-year decrease of -1.
2%.

The original drugs are mainly concentrated in anti-tumor, digestion (diabetes), respiratory, nervous system and other therapeutic fields, and their products are innovative therapeutic drugs in the market, with large market demand, but in the past two years, they have been greatly affected by the centralized procurement policy, and the original drugs included in the centralized procurement have dropped
sharply regardless of whether they are selected or not.

2022H1 The proportion and year-on-year growth distribution of terminal original and generic drugs in China's public medical institutions

04.
The sales of national talk varieties in exchange for price have increased significantly

The implementation of the 21 versions of the national negotiation varieties began in 2022, involving a total of 260 brands, and the sales in the first half of 2022 reached 60 billion yuan
.

The varieties in the negotiation catalogue are all highly innovative and high-priced varieties, which have achieved a significant increase in sales through national price reductions and increased patient accessibility, especially the 56 new varieties included in medical insurance negotiations, with a growth rate of more than 7 times in the first half of 2022; The varieties with agreement period and renewal also maintained a high growth rate; The varieties of conventional medical insurance transfer to negotiation, because they have a good foundation in the market, through negotiation and then price reduction, the promotion of sales increase is relatively small
.

21st edition of the negotiation catalogue variety market sales table in the first half of 2022

05.
The sales of chemical drugs affected by collective procurement and epidemic prevention and control are declining

From the perspective of the sales growth rate of various therapeutic categories of chemical drugs (including biological drugs), there are three main categories of sales decline:

First, due to the impact of centralized procurement (especially the third to fifth batches), the sales of digestive system and metabolites and miscellaneous (mainly contrast agents) in the first half of 2022 showed negative year-on-year growth;

Second, due to the impact of the restrictions on the use of four types of drugs in centralized procurement and epidemic prevention and control, the sales of systemic anti-infective drugs and respiratory drugs in the first half of 2022 showed negative year-on-year growth;

Third, the sales of neurological drugs affected by centralized procurement and the national key monitoring drug catalogue also showed negative growth
in the first half of 2022.
Sales in the rest of the categories showed varying degrees of growth, especially dermatological drugs, with a growth rate of nearly 20%.

2022H1 The proportion and year-on-year growth distribution of terminal chemical drugs (including biological drugs) in China's public medical institutions

Note: Biological drugs are contained in the chemical here

06.
The sales of proprietary Chinese medicines with a high proportion of traditional Chinese medicine injections and greatly affected by epidemic prevention and control showed negative growth

From the sales growth rate of each treatment category of proprietary Chinese medicine in the first half of 2022, the use of cardiovascular and cerebrovascular diseases and tumor diseases, which account for a large proportion of traditional Chinese medicine injections, has shown a downward trend.
Among respiratory diseases, affected by the decline in sales of colds, cough suppressants, detoxification and antiviral drugs, the overall sales of these drugs also showed a downward trend.
The sales of other proprietary Chinese medicine categories have increased to varying degrees, especially those for qi and blood replenishment and dermatology, both of which have a growth rate of more than 15%.

2022H1 China's public medical institutions terminal proprietary Chinese medicine proportion and year-on-year growth distribution table

07.
The TOP10 chemical pharmaceutical companies with a number of 21 editions of national talk drugs and blockbuster new drugs are eye-catching

From the distribution of the top 10 chemical drugs (including biological drugs) in the first half of 2022, there are 6 foreign-funded enterprises and 4 local enterprises, whose sales are relatively concentrated in categories accounting for more than 10% of sales, of which antitumor drugs and chronic diseases of the digestive system, cardiovascular and cerebrovascular system and nervous system are the main
drugs.

Among the TOP10 enterprises, there are many varieties included in the 21st edition of the national negotiation catalogue and enterprises with blockbuster new drugs on the market, and the growth rate of sales in the first half of 2022 has shown an increasing trend, such as semeglutide injection will be launched in China in 2022, bringing new growth highlights
to Novo Nordisk's sales performance.

2022H1 The proportion and year-on-year growth distribution of the top 10 chemical pharmaceutical enterprises in China's public medical institutions

Note: Biological drugs are contained in the chemical here

08.
The sales growth rate of TOP10 proprietary Chinese medicine enterprises with a large proportion of pediatric drugs is relatively high

Judging from the distribution of the top 10 enterprises of proprietary Chinese medicine in the first half of 2022, the companies on the list are all local companies
.

The sales of TOP10 companies are also relatively concentrated in categories that account for more than 10% of sales, of which cardiovascular and cerebrovascular systems, digestive systems and pediatric drugs are the mainstay
.

Among the TOP10 enterprises, except for the year-on-year sales growth rate of Yiling Pharmaceutical, Buchang Group and Tasly, the rest of the enterprises have increased to varying degrees, especially the sales growth rate of Jichuan Pharmaceutical, Kangyuan Pharmaceutical and Lunan Pharmaceutical, which account for a large proportion of pediatric drugs
.

2022H1 China's public medical institutions terminal TOP10 proprietary Chinese medicine enterprises proportion and year-on-year growth distribution table

Data source: Competition pattern of proprietary Chinese medicine terminals in China's public medical institutions on Intranet

Data description: The Intranet China Public Medical Institution Terminal Competition Pattern Database is an enlarged version of the drug sales database
that exclusively realizes the coverage of all terminals of China's public medical institutions (including urban public hospitals, county-level public hospitals, urban community centers, and township health centers) and continuously monitors all categories of chemical drugs (including biological drugs) and proprietary Chinese medicines.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.